DayTwo is the leading microbiome-based precision medicine company, developing personalized nutrition, diagnostic, and therapeutic solutions using AI and machine learning on microbial genomics, human traits, and disease.
Balance blood glucose levels for people with Type II diabetes.
Our initial product enables glycemic-control and is targeted for people with Type II diabetes, helping them balance blood sugar levels, lower HbA1C, and lose weight using a “food-asmedicine” approach, personalized to the subject’s clinical and personal traits.
Future product line:
DayTwo has the largest full-shotgun database of the gut-microbiome in the world. The database is the foundation for the DayTwo Human Discovery Platform™ to identify precision medicine therapies, diagnostics, and care solutions for metabolic and other diseases.
A 2017 market study by Transparency Market research (TMR) estimates the worldwide market for human microbiome-based diagnostics and therapeutics will reach US 3.2 bn in revenues by the end of 2024. DayTwo believes the overall market opportunity is much larger than that.
||Health, Nutrition, Big data
|Legal form||Ltd. company|
|Headquarters||Moshav Adanim, Israel
Walnut Creek, California